The technology involves the development of quaternary ammonium compounds with antimicrobial properties, effective against various bacteria and fungi, including multidrug-resistant strains. These compounds concentrate activity in the gastrointestinal tract, minimizing systemic exposure and potential side effects, making them suitable for conditions like irritable bowel syndrome.
The treatment of bacterial infections, particularly those caused by multidrug-resistant (MDR) strains, poses a significant challenge due to the increasing prevalence of antibiotic resistance. This resistance is especially problematic in hospital settings, where infections with MDR pathogens like S. aureus, A. baumannii, and C. difficile are common. Additionally, the development of new antibiotics has not kept pace with the emergence of resistant strains, leading to a pressing need for novel antimicrobial agents.
Existing approaches often involve the use of broad-spectrum antibiotics, which can disrupt the naturally beneficial microbiome and lead to further complications such as secondary infections and increased resistance. Moreover, many antibiotics are systemically absorbed, which can lead to side effects and limit their use in certain populations. Therefore, there is a need for new antimicrobial agents that are effective against resistant strains, have minimal systemic absorption to reduce side effects, and can target specific pathogens without disturbing the beneficial microbiota.
The described technology revolves around a series of ammonium compounds characterized by a quaternary ammonium structure. These compounds contain a pharmaceutically acceptable anion (A), a variable group (Y) that can be an ester, amide, or sulfonamide, and a flexible alkylene chain (Z). The substituents (R′, R′′, R′′′, R′′′′, and R′′′′′) are diverse, including alkyl, cycloalkyl, aryl, heterocyclyl, and heteroaryl groups, with at least one being an alkoxy group to enhance antimicrobial activity.
These compounds are effective against both Gram-positive and Gram-negative bacteria, as well as fungi, including their multidrug-resistant strains. They are designed to treat bacterial infections by concentrating their activity in the gastrointestinal tract, thereby minimizing systemic exposure and potential side effects, making them suitable for conditions like irritable bowel syndrome (IBS). The compounds are stable in the presence of gut enzymes and have a low propensity for inducing resistance, enhancing their therapeutic potential.
What differentiates this technology is its targeted approach to antimicrobial therapy. The compounds are designed to be poorly absorbed, concentrating their antimicrobial activity within the gastrointestinal tract. This design minimizes systemic exposure and reduces the risk of side effects, which is particularly beneficial for conditions like IBS where altering the gut microbiome is advantageous. Additionally, the compounds exhibit significant stability in the presence of gut enzymes and a low propensity for inducing resistance, making them a robust option for treating multidrug-resistant bacterial infections. The diverse substituents and the inclusion of alkoxy groups further enhance the antimicrobial efficacy, providing a broad-spectrum solution against various pathogens. This combination of targeted activity, stability, and broad-spectrum efficacy sets these ammonium compounds apart from conventional antimicrobial agents.
Issued patent US 11,952,330